UroStream

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic UTUC.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. As one of the premier global academic meetings in genitourinary oncology, the conference showcased multiple landmark studies that are reshaping clinical practice worldwide.

As hematologic malignancy treatment advances toward precision medicine and cellular therapy, relapsed/refractory mixed phenotype acute leukemia (MPAL) remains a major clinical challenge due to its rarity and aggressive nature.

At the 52nd EBMT Annual Meeting held in Madrid in March 2026, the team led by Prof. Zhang Yajing presented a novel therapeutic approach targeting one of the most challenging clinical scenarios in hematology—early relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Non–muscle-invasive bladder cancer (NMIBC) carries a substantial risk of postoperative recurrence, particularly in high-risk and very high-risk patients, where the 5-year recurrence rate can exceed 50%. In recent years, beyond traditional Bacillus Calmette–Guérin (BCG) intravesical therapy, the emergence of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has provided new therapeutic options to reduce recurrence risk in high-risk NMIBC.

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights into the integration of immunotherapy with radiotherapy. We invited Professor Aly-Khan A. Lalani from the Juravinski Cancer Centre at McMaster University, Canada, to discuss the study design, clinical implications, and future directions in the field.

The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an oral session, drawing significant international attention.

The 2026 European Association of Urology Annual Congress (EAU26), one of the most prestigious global meetings in urology, brought together leading advances in urologic oncology. Multiple studies on precision diagnosis of prostate cancer from the team led by Prof. Kan Gong and Prof. Yi Liu at Peking University First Hospital were selected for presentation, showcasing contributions from Chinese researchers on the international stage. Oncology Frontier invited Prof. Gong to share detailed insights into these findings.

During the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), a major breakthrough drew global attention: the first international external validation of the digital pathology–based AI predictive model MMAI in localized prostate cancer. Oncology Frontier – UroStream conducted an on-site interview with Prof. Anna Wilkins, Honorary Consultant in Clinical Oncology at The Institute of Cancer Research and The Royal Marsden Hospital (UK), who provided an in-depth interpretation of the study’s clinical value, real-world implementation prospects, and the broader advances highlighted at this year’s congress.